Clinical Trials Logo

Clinical Trial Summary

This is an open-label, multicenter, non-randomized extension study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and do not have access to the study treatment locally, continue to receive study treatment in this extension study.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05112965
Study type Interventional
Source Hoffmann-La Roche
Contact Reference Study ID Number: YO42713 https://forpatients.roche.com
Phone 888-662-6728 (U.S. Only)
Email [email protected]
Status Recruiting
Phase Phase 3
Start date November 4, 2021
Completion date November 21, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT01938846 - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors Phase 1
Completed NCT03308942 - Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Phase 2
Completed NCT01343043 - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Phase 1
Completed NCT01938638 - Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Phase 1
Recruiting NCT02292641 - The Beyond TME Trial N/A
Terminated NCT00954512 - Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) Phase 1/Phase 2
Recruiting NCT04958239 - A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT01222728 - Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Recruiting NCT03190811 - Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT02806557 - Profiling Neutrophil Counts in Patients on Chemotherapy N/A
Completed NCT02909348 - Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab
Recruiting NCT02514512 - Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking Phase 1
Completed NCT02636426 - Sorafenib Administered Using a High-dose, Pulsatile Regimen: a Phase I Exposure Escalation Study Phase 1
Completed NCT01915576 - Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients Phase 1
Completed NCT01911936 - A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors Phase 1
Suspended NCT01562626 - Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors Phase 1/Phase 2
Completed NCT01688557 - Trial on Innovative Technologies in Colonoscopy N/A